Heart Disease

Top 5 Most-Read Conference Stories of 2020

Empagliflozin met the study's primary end point by reducing the risk of cardiovascular death or hospitalization for heart failure by 25%. Read the full …

Read more at www.ajmc.com

Show More

Related Articles

Back to top button